Treatment with docetaxel has been shown to increase Ki-67 positivity in cancer cells in an IL-6–dependent manner, while neutralization of IL-6—particularly when combined with granulocyte colony-stimulating factor (G-CSF)—significantly reduces this proliferation-inducing effect. The gene discussed is IL6; the disease is cancer.